BAY 2666605

CAS No. 2275774-60-0

BAY 2666605( —— )

Catalog No. M28912 CAS No. 2275774-60-0

BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 258 In Stock
5MG 235 In Stock
10MG 376 In Stock
25MG 828 In Stock
50MG 1293 In Stock
100MG 2074 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BAY 2666605
  • Note
    Research use only, not for human use.
  • Brief Description
    BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.
  • Description
    BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.(In Vitro):BAY 2666605 inhibits brain cancer(glioma, more specifically glioblastoma, astrocytoma), breast cancer (ductal carcinoma and adenocarcinoma), cervical cancer, AML(erythroleukemia), lung cancer(NSCLC adenocarcinoma and SCLC), skin cancer(melanoma), esophagus cancer (squamous cell carcinoma), ovarian cancer, (teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer.(In Vivo):In murine xenotransplantation models of human cancer, BAY 2666605 (5 mg/kg; p.o) exhibits anti-tumor efficacy.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    Wnt
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2275774-60-0
  • Formula Weight
    352.28
  • Molecular Formula
    C17H12F4N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (709.66 mM)
  • SMILES
    C[C@@H]1OC(=O)NN=C1C1=CC=C(C2=CC=C(F)C=C2)C(=C1)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Basu D, et al. Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther. 2014 Jun;13(6):1457-67.
molnova catalog
related products
  • CDP-840 hydrochlorid...

    CDP-840 (CDP840;L-765527) is a potent and selective PDE4 inhibitor with IC50 of 4-45 nM.

  • Imazodan

    Imazodan, a small molecule compound with positive inotropic activity, is a selective type III phosphodiesterase inhibitor and can be used to study heart failure.

  • OPC18750 HCl

    OPC18750 HCl is a potential phosphodiesterase inhibitor with positive inotropic effects that can be used to study asthma, cancer, diabetes, and psychiatric disorders.